Implementation of an antimicrobial stewardship program on the medical-surgical service of a 100-bed community hospital

Antimicrobial Resistance and Infection Control

Donald F Storey¹  Perry G Pate¹  Autumn TT Nguyen²  Fung Chang³ 

[1] Dallas ID Associates, Dallas, Texas, USA

[2] Medical City Dallas Hospital, Dallas, Texas, USA

[3] Medical Center of McKinney, McKinney, Texas, USA

关键词: Small community hospital;    ASP;    Antimicrobial stewardship;   

Others  :  791099
DOI  :  10.1186/2047-2994-1-32

 received in 2012-05-22, accepted in 2012-10-04,  发布年份 2012

【 摘 要 】

Background

Antimicrobial stewardship has been promoted as a key strategy for coping with the problems of antimicrobial resistance and Clostridium difficile. Despite the current call for stewardship in community hospitals, including smaller community hospitals, practical examples of stewardship programs are scarce in the reported literature. The purpose of the current report is to describe the implementation of an antimicrobial stewardship program on the medical-surgical service of a 100-bed community hospital employing a core strategy of post-prescriptive audit with intervention and feedback.

Methods

For one hour twice weekly, an infectious diseases physician and a clinical pharmacist audited medical records of inpatients receiving systemic antimicrobial therapy and made non-binding, written recommendations that were subsequently scored for implementation. Defined daily doses (DDDs; World Health Organization Center for Drug Statistics Methodology) and acquisition costs per admission and per patient-day were calculated monthly for all administered antimicrobial agents.

Results

The antimicrobial stewardship team (AST) made one or more recommendations for 313 of 367 audits during a 16-month intervention period (September 2009 – December 2010). Physicians implemented recommendation(s) from each of 234 (75%) audits, including from 85 of 115 for which discontinuation of all antimicrobial therapy was recommended. In comparison to an 8-month baseline period (January 2009 – August 2009), there was a 22% decrease in defined daily doses per 100 admissions (P = .006) and a 16% reduction per 1000 patient-days (P = .013). There was a 32% reduction in antimicrobial acquisition cost per admission (P = .013) and a 25% acquisition cost reduction per patient-day (P = .022).

Conclusions

An effective antimicrobial stewardship program was implemented with limited resources on the medical-surgical service of a 100-bed community hospital.

【 授权许可】

   
2012 Storey et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]National Center for Health Statistics: Health, United States, 2010; With Special Feature on Death and Dying. Hyattsville, MD; 2010.
• [2]Dudeck MA, Horan TC, Peterson KD, Allen-Bridson K, Morrell G, Pollock DA, Edwards JR: National Healthcare Safety Network (NHSN) report, data summary for 2010, device-associated module. Am J Infect Control 2011, 39:798-816.
• [3]Klevens RM, Edwards JR, Gaynes RP: National Nosocomial Infections Surveillance System. The impact of antimicrobial-resistant, healthcare-associated infections on mortality in the United States. Clin Infect Dis 2008, 47:927-930.
• [4]Jernigan JA: Overview of antimicrobial resistance -- antibacterial resistance. FDA Public Meeting: Antibacterial Resistance and Diagnostic Device and Drug Development Research for Bacterial Diseases. Public Workshop, Silver Spring, MD, 26-27 July; 2010. http://www.fda.gov/downloads/Drugs/NewsEvents/UCM226072.pdf webcite
• [5]Campbell RJ, Giljahn L, Machesky A, Cibulskas-White K, Lane LM, Porter K, Paulson JO, Smith FW, McDonald LC: Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect Control Hosp Epidemiol 2009, 30:526-533.
• [6]Bartlett JG: A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis 2011, 53(Suppl 1):4-7.
• [7]Septimus EJ, Owens RC Jr: Need and potential of antimicrobial stewardship in community hospitals. Clin Infect Dis 2011, 53(Suppl 1):8-14.
• [8]Ohl CA, Dodds Ashley ES: Antimicrobial stewardship programs in community hospitals: the evidence base and case studies. Clin Infect Dis 2011, 53(Suppl 1):23-28.
• [9]Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
• [10]Barlam TF, DiVall M: Antibiotic-stewardship practices at top academic centers throughout the United States and at hospitals throughout Massachusetts. Infect Control Hosp Epidemiol 2006, 27:695-703.
• [11]Trivedi K, Rosenberg J: The state of antimicrobial stewardship programs in California.. 21st Annual Scientific Meeting of the Society for Healthcare Epidemiology of America, Dallas, TX 1-4 April; 2011: [Abstract 376]. http://shea.confex.com/shea/2011/webprogram/Paper4907.html webcite
• [12]Johannsson B, Beekman SE, Srinivasan A, Hersh AL, Laxminarayan R, Polgreen PM: Improving antimicrobial stewardship: the evolution of programmatic strategies and barriers. Infect Control Hosp Epidemiol 2011, 32:367-374.
• [13]Kuntz JL, Cavanaugh JE, Becker LK: Clostridium difficile-associated disease in patients in a small rural hospital. Infect Control Hosp Epidemiol 2007, 28:1236-1239.
• [14]LaRocco A Jr: Concurrent antibiotic review programs – a role for infectious diseases specialists at small community hospitals. Clin Infect Dis 2003, 37:742-743.
• [15]National Healthcare Safety Network (NHSN): Multidrug-Resistant Organism & Clostridium difficile Infection (MDRO/CDI) Module Protocol. http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf webcite
• [16]Carling P, Fung T, Killion A, Terrin N, Barza M: Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003, 24:699-706.
• [17]Ruttiman S, Keck B, Hartmeier C, Maetzel A, Bucher HC: Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis 2004, 38:348-356.
• [18]Fraser GL, Stogsdill P, Dickens JD Jr, Wennberg DE, Smith RP, Prato S: Antibiotic optimization. An evaluation of patient safety and economic outcomes. Arch Int Med 1997, 157:1689-1694.
• [19]Filius PMG, Liem TB, van der Linden PD, Janknegt R, Natsch S, Vulto AG, Verbrugh HA: An additional measure for quantifying antibiotic use in hospitals. J Antimicrob Chemother 2005, 55:805-808.
• [20]Ansari F, Molana H, Goossens H, Davey P: Development of standardized methods for analysis of changes in antibacterial use in hospitals from 18 European countries: the European Surveillance of Antimicrobial Consumption (ESAC) longitudinal survey, 2000–06. J Antimicrob Chemother 2010, 65:2686-2691.
• [21]Jacob JT, Gaynes RP: Emerging trends in antibiotic use in US hospitals: quality, quantification and stewardship. Expert Rev Anti Infect Ther 2010, 8:893-902.
• [22]Stevens V, Dumyati G, Fine LS, Fisher SG, van Winjgaarden E: Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011, 53:42-48.
• [23]Werner NL, Hecker MT, Sethi AK, Donskey CJ: Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis 2011, 11:187. BioMed Central Full Text
• [24]me: Centers for Medicaid and Medicare Services and The Joint Commission Specifications Manual for National Hospital Inpatient Quality Measures. http://www.jointcommision.org/specifications_manual_for_national_hospital_inpatient_quality_measures.aspx webcite
• [25]Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L: Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41:1254-1260.
• [26]MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE: Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005, 41:435-440.
• [27]Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y: Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008, 52:1028-1033.
• [28]Fong KS, Fatica C, Hall G, Procop G, Schindler S, Gordon SM, Fraser TG: Impact of PCR testing for Clostridium difficile on incident rates and potential on public reporting: is the playing field level? Infect Control Hosp Epidemiol 2011, 32:932-933.
• [29]Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.